MultiCell Technologies(OTC) MCET

Current Price$0.00

Market Cap$5.00K

Since IPO (1991)-100%

5 Year-100%

1 Year+0%

1 Month+0%

MultiCell Technologies last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-20

MultiCell Technologies stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-13
1 month	+0%	USD 0.00	2026-06-18
3 month	+0%	USD 0.00	2026-04-20
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-07-18
3 year	-50%	USD 0.00	2023-07-13
5 year	-99.87%	USD 0.00	2021-07-21
Since inception	-100%	USD 259.46	1991-09-26

MultiCell Technologies Financials at a Glance

Market Cap

$5.00K

Revenue (TTM)

$805.24

Net Income (TTM)

-$253.61

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-23.76 (Low)

Dividend

$0.00

Beta (Volatility)

-23.76 (Low)

Price

$0.00

Volume

4,000

Open

$0.00

Price

$0.00

Volume

4,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jan 29, 2025

Dividend

$0.00

Beta (Volatility)

-23.76 (Low)

Price

$0.00

Volume

4,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jan 29, 2025

MCET News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MultiCell Technologies

MultiCell Technologies, Inc. operates as a biopharmaceutical firm focused on developing innovative therapeutic agents and research tools. The company addresses various medical challenges, including neurological conditions, liver ailments, and cancer treatments.

Products and Services

MCT-125: Investigational therapy in Phase II trials for multiple sclerosis fatigue
MCT-465: Preclinical synthetic dsRNA candidate for solid tumor treatment
Ideal BioStent: Bioabsorbable stent for interventional cardiology applications

Growth Outlook

Strong pipeline with multiple candidates targeting significant medical needs
Partnerships with industry leaders like Corning and Pfizer enhance credibility
Focus on innovative therapies positions the company for future growth

Financial Highlights

Recent quarterly revenue of $194.77K, showing potential for growth
Trailing twelve months (TTM) revenue of $585.81K indicates upward trend
Operating income margin improvement from -23.43% to -14.66% over time

MultiCell Technologies, Inc. is dedicated to addressing critical health issues through its innovative product pipeline. The company’s focus on developing therapies for complex conditions, combined with strategic partnerships, positions it well for future growth. Recent financial data reflects a positive trajectory, with increasing revenue and improving operating margins. Investors may find the company's commitment to research and development, along with its unique product offerings, appealing as it navigates the biopharmaceutical landscape.

AI Generated • Jul 1, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Woonsocket, RI 02895, US

MCET Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1465.60%

Net Income Margin

-770.65%

Return on Equity

164.07%

Return on Capital

-860.17%

Return on Assets

-301.11%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.00K

Shares Outstanding

5.00B

Volume

4.00K

Avg. Volume

706.01K

Financials (TTM)

Gross Profit

$523.01

Operating Income

-$479.94

EBITDA

-$251.20K

Operating Cash Flow

-$196.89

Capital Expenditure

-$0.91

Free Cash Flow

-$197.80

Cash & ST Invst.

$281.12

Total Debt

$149.08

MultiCell Technologies Performance Analysis

MultiCell Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2014-11-30	0.0%
Q1	2015-02-28	-0.0%
Q2	2015-05-31	4651.4%
Q3	2015-08-31	-66.8%

MultiCell Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2014-11-30	-101.7%
Q1	2015-02-28	87.0%
Q2	2015-05-31	35342.8%
Q3	2015-08-31	-190.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2015YOY CHG

Revenue

$194.77

+1479.8%

Gross Profit

$46.23

+275.0%

Gross Margin

23.74%

N/A

Market Cap

$5.00K

N/A

Market Cap/Employee

$2.50K

N/A

Employees

N/A

Net Income

-$159.30

-170.8%

EBITDA

-$171.35K

-185.2%

Quarterly Fundamentals

Name

Q3 2015YOY CHG

Total Cash

$281.12

+113.9%

Total Debt

$149.08

+148.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$35.33K

N/A

Return on Assets

-3.01%

N/A

Return on Invested Capital

68.52%

N/A

Free Cash Flow

-$78.87

+63.2%

Operating Cash Flow

-$78.87

+63.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BNGIBangi Inc.

BNGIBangi Inc.$0.00+0.00%

YECOEV Biologics, Inc.

YECOEV Biologics, Inc.$0.00+0.00%

PFNDPathfinder Cell Therapy, Inc.

PFNDPathfinder Cell Therapy, Inc.$0.00+0.00%

BPTSYBiophytis S.A.

BPTSYBiophytis S.A.$0.25+0.00%

VIRXViracta Therapeutics, Inc.

VIRXViracta Therapeutics, Inc.$0.01+0.00%

CBDGTHC Farmaceuticals, Inc.

CBDGTHC Farmaceuticals, Inc.$0.03+0.00%

TSOITherapeutic Solutions International, Inc.

TSOITherapeutic Solutions International, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About MCET

What is the current price of MultiCell Technologies?

MultiCell Technologies is trading at $0.00 per share.

What is the 52-week range for MultiCell Technologies?

Over the past 52 weeks, MultiCell Technologies has traded between $0.00 and $0.00.

How much debt does MultiCell Technologies have?

MultiCell Technologies total debt is unavailable.

How much cash does MultiCell Technologies have on hand?

MultiCell Technologies does not have cash on hand data available.

What is MultiCell Technologies’s dividend yield?

MultiCell Technologies does not currently have a dividend yield.

MultiCell Technologies(OTC) MCET

MultiCell Technologies Financials at a Glance

MCET News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MultiCell Technologies

MCET Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MultiCell Technologies Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MCET

What is the current price of MultiCell Technologies?

What is the 52-week range for MultiCell Technologies?

How much debt does MultiCell Technologies have?

How much cash does MultiCell Technologies have on hand?

What is MultiCell Technologies’s dividend yield?

Premium Investing Services